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Vitamin D as a novel 
nontraditional risk factor for 
mortality in hemodialysis 
patients: The need for 
randomized trials
Z Al-Aly1–3
Vitamin D has been used in the context of secondary 
hyperparathyroidism in patients with end-stage renal disease. A wave 
of recent studies suggests that vitamin D treatment may be associated 
with decreased mortality risk in these patients. The article by Wolf et al. 
further supports these studies by identifying vitamin D deficiency as a 
risk factor for early mortality in incident hemodialysis patients.
Kidney International (2007) 72, 909–911. doi:10.1038/sj.ki.5002544
1Division of Nephrology, Saint Louis University, 
Saint Louis, Missouri, USA; 2Division of Nephrology, 
Saint Louis Veterans Affairs Medical Center, Saint 
Louis, Missouri, USA; and 3Saint Louis Veterans 
Affairs Clinical Research and Epidemiology Center, 
Saint Louis, Missouri, USA
Correspondence: Z Al-Aly, Division of Nephrology, 
Saint Louis University Hospital, 3635 Vista Avenue, 
FDT 9N, Saint Louis, Missouri 63110, USA. 
E-mail: zalaly@slu.edu
Vitamin D has been used in the context 
of secondary hyperparathyroidism in 
patients with chronic kidney disease. 
Recently a body of evidence started to 
emerge pointing to the high prevalence 
of vitamin D deﬁciency and suggesting 
that, beyond its effect on parathyroid 
hormone (PTH) and divalent ion homeo-
stasis, vitamin D replacement may aﬀect 
survival in patients with end-stage renal 
disease (ESRD). However, the effect 
of vitamin D treatment on survival in 
patients with ESRD has been examined 
only in retrospective studies. A historical 
cohort study of 51,037 patients on hemo-
dialysis suggested that patients treated 
with activated injectable vitamin D had a 
2-year survival beneﬁt of 20% compared 
with patients who did not receive any 
activated injectable vitamin D treatment 
(hazard ratio 0.80, 95% conﬁdence inter-
val 0.76–0.83, P < 0.01).1 These results 
were echoed in another cohort study, 
which examined mortality associated 
with vitamin D use in 14,967 incident 
hemodialysis patients in a not-for-proﬁt 
dialysis network. The results revealed that 
almost half of the patients (46.9%) did not 
receive any injectable vitamin D and that 
those patients (6,855) had an increased 
mortality risk with a hazard ratio of 1.20 
(1.10–1.32, P < 0.05).2 Another study of 
1,007 incident hemodialysis and perito-
neal dialysis patients showed 26% lower 
mortality in patients who received calci-
triol compared with those who did not 
receive any vitamin D (hazard ratio 0.74 
(0.56–1.00), P < 0.05).3 In a Japanese 
study of 242 hemodialysis patients, there 
was no diﬀerence in the risk of death from 
non-cardiovascular disease in patients 
who received α-calcidol and those who 
did not. The use of α-calcidol, however, 
signiﬁcantly lowered the risk of death due 
to cardiovascular disease (hazard ratio 
0.287 (0.13–0.65), P = 0.003).4
These results are not universal and 
depend to a signiﬁcant degree on the 
statistical model used and the covari-
ates included in the regression analysis. 
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Using a ﬁxed-covariate Cox statistical 
model that adjusts for demographic, 
comorbid conditions, dialysis effi-
ciency, nutritional and inﬂammatory 
parameters, and baseline laboratory 
values, Kalantar-Zadeh et al.5 did not 
ﬁnd any survival advantage for pari-
calcitol use in maintenance dialysis 
patients. However, when the investiga-
tors used time-dependent Cox models 
with time-varying repeated measures, 
they were able to show a significant 
survival advantage in patients who 
received paricalcitol compared with 
those who did not receive any activated 
injectable vitamin D. The investigators 
stratiﬁed patients into groups accord-
ing to weekly vitamin D doses received 
(1–4.9, 5–9.9, 10–14.9, and ≥15 µg per 
week) and, interestingly, found that this 
survival beneﬁt was diluted in patients 
receiving incrementally higher doses of 
paricalcitol. The study did not address 
whether there was a threshold dose 
beyond which the survival advantage 
was neutralized but noted that patients 
who received higher doses of paricalci-
tol had higher PTH levels. Because the 
statistical model controlled for the eﬀect 
of PTH, it is unlikely that the decrease 
in survival beneﬁt in patients receiv-
ing higher doses of paricalcitol is due 
to higher PTH. The investigators in 
this study concluded that this eﬀect is 
analogous to the increased risk of death 
seen in maintenance dialysis patients 
requiring high doses of recombinant 
erythropoietin and that this increased 
risk is likely to be due to the presence 
of inflammation and erythropoietin 
resistance. Whether this diluted survival 
beneﬁt is due to the use of higher doses 
of paricalcitol or to the presence of fac-
tors that inﬂuence survival that were 
unaccounted for in the analysis cannot 
be determined.5
Differences among vitamin D analogues
Only a few retrospective studies have 
examined the effect of different vita-
min D analogues on survival in ESRD 
patients. A large historical cohort study 
examined survival of 67,399 hemodialy-
sis patients who received treatment with 
intravenous paricalcitol or calcitriol in 
a large for-proﬁt national dialysis net-
work in the United States. During the 
36-month study period, the mortality 
rate in the paricalcitol group was 16% 
lower than that in the calcitriol group 
(relative risk ratio 0.84, 95% conﬁdence 
interval 0.79–0.90, P < 0.001).6
However, in the study referred to ear-
lier, Tentori and collaborators2 examined 
mortality risk and use of vitamin D in 
14,967 incident hemodialysis patients 
in a not-for-proﬁt dialysis network and 
found that, in comparison with calcitriol, 
the adjusted risk for all-cause mortality 
was not signiﬁcantly diﬀerent in those 
patients receiving paricalcitol, or doxer-
calciferol. There was also no signiﬁcant 
diﬀerence in the risk for all-cause mor-
tality in patients receiving paricalcitol 
versus doxecalciferol. These results sug-
gest that the survival advantage of pari-
calcitol- versus calcitriol-treated patients 
may be signiﬁcantly smaller than previ-
ously reported and that within not-for-
proﬁt facilities, diﬀerences in mortality 
between patients receiving diﬀerent vita-
min D analogues may be negligible.2
Vitamin D deficiency: A novel risk factor 
for mortality in patients with end-stage 
renal disease
Mortality in patients on dialysis is very 
high. Traditional risk factors, although 
highly prevalent in patients on dialysis, 
do not fully explain the increased mor-
tality in this patient population.7–9 The 
gap between the high observed mortality 
and that expected when traditional risk 
factors are accounted for suggests the 
presence of risk factors that are not yet 
identiﬁed and are therefore unaccounted 
for in risk analysis.
Wolf et al.10 (this issue) examined the 
relationship between 25-hydroxyvitamin 
D and 1,25-hydroxyvitamin D levels and 
90-day mortality in a nested case-control 
study sample of 1,000 incident hemo-
dialysis patients in a for-proﬁt dialysis 
network in North America. The authors 
considered the ﬁrst 750 consecutive sur-
vivors and the ﬁrst 250 patients who died 
within 90 days for survival analysis. The 
authors show that vitamin D deﬁciency 
is very common in patients on hemo-
dialysis. Using a multivariate regression 
model, they show that severe 25-hydroxy-
vitamin D deﬁciency is associated with 
an increased risk of all-cause mortality. 
Interestingly, severe 25-hydroxyvitamin 
D deﬁciency was not signiﬁcantly asso-
ciated with increased risk for cardiovas-
cular mortality. This could be due to the 
small sample size or to the possible eﬀect 
of vitamin D level on non-cardiovascular 
causes of death such as infection, cancer, 
and others. Interestingly, the relationship 
between 1,25-hydroxyvitamin D and all-
cause mortality is less robust and suggests 
perhaps that 25-hydroxyvitamin D is a 
better overall biomarker of survival than 
1,25-hydroxyvitamin D.
The authors go on to demonstrate that 
there is no increase in risk of mortality 
according to 25-hydroxyvitamin D and 
1,25-hydroxyvitamin D levels in patients 
who were subsequently treated with acti-
vated vitamin D.10 Patients were started 
on active vitamin D treatment a median 
of 14 days after initiation of dialysis and 
were treated for a median of 74 days. It 
is extremely interesting that such a short 
treatment duration would greatly inﬂu-
ence the mortality risk. The proposed 
mechanisms underpinning the survival 
Figure 1 | The puzzle of the truth about the effect of vitamin D on mortality in ESRD is not 
complete without randomized trials.
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advantage of vitamin D, including the 
eﬀect on the renin–angiotensin system, 
blood pressure, inﬂammation, glucose 
homeostasis, left ventricular hypertrophy, 
pulmonary physiology, innate immunity, 
endothelial dysfunction, intima–media 
thickness, and incidence of cancer and 
autoimmune diseases, although plau-
sible, are not likely to confer a survival 
advantage in a short duration of time (74 
days).11 Short-term mortality in stud-
ies involving a chronic disease is largely 
determined by comorbid conditions. Is 
it possible that vitamin D prescription is 
inﬂuenced by the physician’s perception 
of patient prognosis? Could it be possible 
that patients who indeed received treat-
ment were healthier, or received better 
overall care? Why did 25-hydroxyvita-
min D and 1,25-hydroxyvitamin D levels 
lose their value as predictors of all-cause 
mortality in patients who were subse-
quently treated with vitamin D for a short 
period of time? It is clear from the data 
presented that patients who died had on 
average lower mean arterial blood pres-
sure, a lower percentage of arteriovenous 
ﬁstulas, a higher percentage of congestive 
heart failure diagnosis, and lower serum 
albumin concentrations. Although these 
speciﬁc parameters are adjusted for in 
the multivariate regression model used 
by the investigators, they are general 
indicators of overall heath and quality of 
health care received, and it is likely that 
there are residual confounders (unknown 
or unmeasured) that were not accounted 
for in the analysis.
The case-control study by Wolf et al.10 
was observational in nature and was not 
randomized. Therefore, the results have 
to be interpreted with caution. Without 
a randomization, it is rather challenging 
to design a study that yields a valid com-
parison of those who received vitamin 
D analogues and those who did not. The 
main challenge stems from a phenom-
enon that epidemiologists refer to as 
‘confounding by indication’. The prob-
lem arises from the fact that patients 
who received vitamin D analogues are 
inherently different from those who 
did not, and any diﬀerence in outcomes 
measured cannot be attributed with cer-
tainty to the use of vitamin D analogues. 
Only randomized studies would prevent 
bias and minimize confounding and 
enable us to conﬁrm these interesting 
observations.
The most important finding of the 
work by Wolf et al.10 is that severe vita-
min D deficiency is associated with 
increased early mortality in incident 
hemodialysis patients. Vitamin D deﬁ-
ciency is often identiﬁed in earlier stages 
of chronic kidney disease. The current 
Kidney Disease Outcomes Quality Ini-
tiative (KDOQI) guidelines recommend 
screening for vitamin D deﬁciency only 
in patients with elevated PTH levels. 
Should all kidney disease patients be 
screened for vitamin D deﬁciency irre-
spective of PTH levels? Should vitamin 
D-deﬁcient patients be treated irrespec-
tive of PTH levels? Is there a real diﬀer-
ence in mortality risk between activated 
vitamin D2 and D3 analogues? Are these 
ﬁndings also relevant in patients with 
less severe chronic kidney disease? What 
are the optimal dose, duration, and goal 
of treatment?
That the association of 25-hydroxyvi-
tamin D with early mortality is stronger 
than that of 1,25-hydroxyvitamin D is 
interesting and suggests that, perhaps 
owing to its stability and reduced assay 
variability, 25-hydroxyvitamin D may 
be a better biomarker. However, the 
quantitative and functional relevance 
of extrarenal 1α-hydroxylase may be 
more pronounced in patients with sig-
niﬁcantly diminished renal functional 
reserve (that is, decreased or absent 
renal 1α-hydroxylase activity), and in 
these patients 25-hydroxyvitamin D 
may exert its beneﬁcial eﬀects through 
paracrine and/or autocrine pathways. 
Whether treatment with prohormones 
(for example, ergocalciferol or chole-
calciferol) in advanced chronic kidney 
disease has any beneﬁcial eﬀects remains 
to be determined.
The fundamental mission of medical 
scientiﬁc undertaking is to alleviate and 
ease human suﬀering. The meritorious 
work of Wolf et al.10 represents a step in 
the right direction and brings to light a 
novel risk factor for early mortality in 
incident hemodialysis patients. These 
ﬁndings further cement the notion that 
there is an intimate relationship between 
vitamin D and mortality in dialysis 
patients. However, we still do not have a 
deﬁnitive answer as to whether vitamin 
D treatment really inﬂuences survival 
in dialysis patients. Further studies are 
needed to elucidate the nature of the 
relationship between this risk factor 
and outcomes in patients with varying 
degrees of chronic kidney disease. It is 
our collective responsibility as physi-
cians, the pharmaceutical industry, 
and government regulatory agencies 
to ensure that appropriately designed 
randomized trials are planned and exe-
cuted to answer these very important 
questions in the hope that the answers 
will advance our understanding of the 
causes of mortality in patients with kid-
ney disease and narrow the gap between 
the expected and observed mortality in 
these patients.
The commendable work by Wolf and 
collaborators10 brings us closer to the 
truth, but the puzzle of the truth about 
the eﬀect of vitamin D on mortality in 
ESRD is unlikely to be complete without 
a randomized trial (Figure 1).
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